BioMedNewsBreaks Archive - Page 94 of 175

MondayJan 10, 2022 1:06 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names Industry Veteran as COO

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has appointed Dr. Arash (Ash) Ghadar as chief operating officer. Currently a non-executive director at Medilink Midlands, Ghadar served for 10 years as the technical director of London-based Datalink Electronics (Datalink), where he managed the design team as an autonomous entity within Datalink. In that capacity, he oversaw the day-to-day operations, business planning, legal affairs, finance, sales and business development of the design team. He also managed numerous technical projects for the company’s healthcare and industrial customers; those…

MondayJan 10, 2022 10:10 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor relations and corporate financial public relations with members of the investment community, the financial media and the general public. The services agreement with JBN has a term of six months with a total payment value of $150,000. In addition, the company today announced that it…

FridayJan 07, 2022 11:42 am

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at H.C. Wainwright Bioconnect Conference

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Dr. Faz Chowdhury will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference. The event is slated to take place on Jan. 10-13, 2022, with Dr. Chowdhury’s presentation available on-demand to registered attendees beginning at 7:00 a.m. ET on Monday, Jan. 10. Interested parties should visit https://ibn.fm/98dTC to register for the conference. To view the full press release, visit https://ibn.fm/1K4uT About Nemaura Medical Inc. Nemaura Medical is a medical…

FridayJan 07, 2022 11:12 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at H.C. Wainwright BioConnect Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that CEO John Climaco will present at the upcoming H.C. Wainwright BioConnect Conference. The conference is slated for Jan. 10-13, 2022. Interested parties who have registered for the event can view the presentation, which will be virtual, at 7 a.m. ET on Jan. 10. A replay of the webcast will be available in CNSP’s investor section of its website for 90 days. To view the presentation, visit https://ibn.fm/KkrtX To view the full press…

ThursdayJan 06, 2022 2:18 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in a recent episode of “Gamechangers LIVE.” The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. Joshua Bartch, Mydecine’s co-founder, chairman and CEO, joined the broadcast, hosted by executive coach and speaker Sergio Tigera, to discuss his background as an entrepreneur spanning multiple successful ventures across a variety of industries. Bartch…

ThursdayJan 06, 2022 1:13 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be participating in the H.C. Wainwright Bioconnect Conference; the multiday conference is scheduled for Jan. 10–13, 2022. According to the announcement, MINDCURE president and CEO Kelsey Ramsden will provide a virtual presentation, which will be available for viewing beginning on Monday, Jan. 10, 2022, at 7 a.m. ET; the presentation will be available for 90 days. Ramsden will also be available for one-on-one meetings. The announcement also noted that MINDCURE has granted a total of 350,000 stock options to specific employees…

ThursdayJan 06, 2022 11:58 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Agreements Totaling $11.5M for Gross Proceeds

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (“CNS”), has entered into securities purchase agreements with several institutional and accredited investors. The agreements outline the issue of more than 12 million shares of common stock, prefunded warrants and warrants in a private placement; the shares and warrants are offered at a purchase price of $0.95 per share. The issuance will result in an estimated $11.5 million gross proceeds for the company. Anticipated closing of the private placement is expected on or about Jan. 10,…

WednesdayJan 05, 2022 2:30 pm

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) Innovative Portfolio Powers Research Insights

RYAH Group (CSE: RYAH) is the leader in volume-control technology for plant-based medicine. The company supports cannabis research for the treatment of cancer “with innovative technology that collects, analyzes and leverages objective data on therapeutic plant usage. By using the company’s smart devices and integrated AI-powered platform, patients and doctors can stay on top of prescription treatments in a safe, secure and seamless way,” reads a recent article. “RYAH’s current portfolio integrates IoT devices, medicine-carrying components and mobile applications to create an ecosystem that enables practitioners and patients to administer treatments, control volume, collect data and produce analytics that can…

WednesdayJan 05, 2022 11:37 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, has released a shareholder letter. The letter, from president and CEO Eric A. Adams, provided INM shareholders with a company update, including a look at key milestones the company had reached, including the acquisition of BayMedica, which Adams said positioned InMed as a clear leader in rare cannabinoid manufacturing. Adams also noted that the company continued to make significant strides with its proprietary IntegraSyn(TM) program and is advancing its pharmaceutical programs, thanks in large part to the library of novel cannabinoid analogs developed by BayMedica.…

WednesdayJan 05, 2022 10:51 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces January 2022 Health Care Conference Schedule

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase. The events are slated to be held virtually on Jan. 10-12, 2022. Tryp’s CEO and Chairman Greg McKee will provide an overview of the company and updates on its chronic pain and eating disorder programs. This year, all corporate presentations will be pre-recorded and available on-demand for registered attendees. In addition, replays of the presentations will be available on the Events section…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names Industry Veteran as COO

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at H.C. Wainwright Bioconnect Conference

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at H.C. Wainwright BioConnect Conference

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Agreements Totaling $11.5M for Gross Proceeds

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) Innovative Portfolio Powers Research Insights

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces January 2022 Health Care Conference Schedule

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search